For a report overview of this report please contact sara.peerun@visiongainglobal.com (+44 (0) 20 7336 6100) or refer to our website: https://www.visiongain.com/blog/pha0133-ss

1. ©notice
This material is copyright by visiongain. It is against the law to reproduce any of this material without the prior
written agreement of visiongain.You cannot photocopy, fax, download to database or duplicate in any other way
any of the material contained in this report. Each purchase and single copy is for personal use only.
Blood Glucose Monitoring Devices World
Market Outlook 2016-2026
Glucose Test Strips, Self-Monitoring Blood Glucose Device, Non-
Invasive Blood Glucose Meter, Continuous Blood Glucose Monitor

2. www.visiongain.com
Contents
1. Executive Summary
1.1 Sector Highlights
1.2 Blood Glucose Monitoring Market Segmentation
1.3 Overview of Findings
1.4 Chapter Outline
1.5 Aims, Scope and Format of the Report
1.6 Who is This Report For?
1.7 Methodology
1.8 Research and Analysis Methods
1.9 Frequently Asked Questions (FAQ)
1.10 Glossary of Terms Related to the Report
1.11 About Visiongain
2. Introduction to Diabetes and Monitoring Devices
2.1 What is Diabetes?
2.1.1 Classifying Diabetes
2.1.2 Symptoms And Long-Term Complications
2.1.3 Treatment
2.1.4 Diagnosis
2.1.5 Diabetes on the global and public agenda
2.2 Diabetes Monitoring
2.2.1 Glucose Levels
2.2.2 Reagent Strips and Glucose Meters
2.2.3 Urine Testing
2.2.4 Haemoglobin A1c Testing
2.2.5 Blood Pressure
2.2.6 Blood Cholesterol
2.2.7 Eye Tests

3. www.visiongain.com
Contents
3. The Global Self Monitoring Blood Glucose Devices Market, 2015-2026
3.1 The Global Diabetes Care Devices Market, 2015
3.2 SMBG Devices Market, 2015
3.3 Global SMBG Devices Market Forecast, 2015-2026
4. Glucose Test Strips Market, 2016-2026
4.1 Glucose Test Strips
4.2 Glucose Test Strips: Market Forecast, 2015-2026
4.2.1 Glucose Test Strips: Industry Trends, 2016-2026
4.3 Companies and Products
4.3.1 Abbott Diabetes Care
4.3.2 Bayer Healthcare
4.3.3 Roche
4.3.4 LifeScan
4.3.5 Nipro Diagnostics
5. Glucose Meters Market, 2016-2026
5.1 Glucose Meters
5.1.1 How It Works
5.2 Marketed Glucose Meters
5.3 Glucose Meters: Market Forecast, 2015-2026
5.3.1 Technology Advancements
5.3.2 Growing Significance of Emerging Markets
5.3.3 Blood Glucose Meters of Particular Interest
5.3.4 Emergence of CGMs

4. www.visiongain.com
Contents
6. Continuous Glucose Monitoring Market, 2016-2026
6.1 Continuous Glucose Monitoring (CGM)
6.2 Continuous Glucose Monitoring Market, 2015
6.3 Continuous Glucose Monitoring (CGM) Systems vs. Fingertip Testing
6.3.1 The CGM Pipeline
6.4 Continuous Glucose Monitoring: Market Forecast, 2015-2026
6.5 Continuous Glucose Monitoring: Industry Trends, 2016-2026
6.5.1 Improved Glucose Control
6.5.2 The US is the Largest Market for CGMs
6.5.3 Challenges to Growth of CGMs
7. Leading Companies in the SMBG Devices Market, 2015
7.1 Market Showing Signs of Recovery
7.2 SMBG Devices Market: Breakdown By Company, 2015
7.3 Roche
7.3.1 Sales and Recent Performance Analysis
7.3.2 Roche Diagnostics
7.3.3 Marketed Glucose Meters
7.4 Abbott Laboratories
7.4.1 Sales and Recent Performance Analysis
7.4.2 Abbott Geographic Sales
7.4.3 Marketed Glucose Meters
7.5.1 Sales and Recent Performance Analysis, 2015
7.5.1.1 Medical Devices And Diagnostics (MD&D)
7.5.2 J&J Geographic Sales
7.5.3 Marketed Glucose Meters
7.6 Bayer Healthcare
7.6.1 Sales and Recent Performance Analysis, 2015
7.6.2 Bayer Healthcare Geographic Sales

5. www.visiongain.com
Contents
7.6.3 Marketed Glucose Meters
7.7 Other Companies
8. Leading National SMBG Devices Markets, 2015-2026
8.1 Regional Breakdown of The Global Diabetes Monitoring Devices Market, 2015
8.2 The Global SMBG Devices Market: Regional Forecast, 2015-2026
8.3 US Medical Device Market
8.3.1 The US Market Forecast: 2015-2026
8.4 The European Market
8.4.1 Changes in the New EU Medical Device Regulations
8.4.2 Post Marketing Surveillance in the EU
8.4.3 Germany
8.4.4 France
8.4.5 Italy
8.4.6 Spain
8.4.7 UK
8.5 The Japanese Market
8.6 The BRIC Market
8.6.1 The Chinese Market
8.6.1.1 New Policies Favouring Domestically-Made Medical Devices
8.6.2 The Indian Market
8.6.3 The Russian SMBG Market
8.6.3.1 Russian SMBG Market Forecast 2015-2026
8.6.4 Brazilian Market Forecast, 2015-2026
8.6.4.1 Brazilian Market Forecast, 2015-2026
8.6.4.2 The Brazillian Market

6. www.visiongain.com
Contents
9. SWOT Analysis of the SMBG Devices Market, 2016
9.1 SMBG Devices: Industry Trends
9.2 Strengths
9.2.1 Effective Disease Management
9.2.2 Technological Advancements
9.2.3 Patient Demographics
9.3 Weaknesses
9.3.1 Regulatory Board Approvals
9.3.2 Benefits Vs. Costs
9.3.3 Reimbursement Issues
9.4 Opportunities
9.4.1 Globalisation: Established and Emerging Markets
9.4.2 Next-Generation Blood Glucose Monitoring
9.4.3 Mobile Applications
9.5 Threats
9.5.1 “Burnout”: Issues with Testing Adherence
9.5.2 Decreasing Investments
10. Opinions from Our Industry Survey
10.1 Interview with Bennet Dunlap of The Diabetes Patient Advocacy Coalition (DPAC)
10.2 The Diabetes Patient Advocacy Coalition (DPAC)
10.3 Patient Safety
10.4 Market Drivers
10.5 Use of Generic Products
10.6 The Future of Blood Glucose Monitoring
10.7 Interview with Dr. Sara Bachmann of the Endocrinology and Diabetology Department;
University Children’s Hospital Basel
10.8 The Endocrinology and Diabetology Department; University Children’s Hospital Basel
10.9 Patient Safety

7. www.visiongain.com
Contents
10.10 Market Drivers
10.11 Use of Generic Products
10.12 The Future of Blood Glucose Monitoring
11. Conclusions
11.1 Overview
11.2 Glucose Test Strips will Remain the Largest Segment
11.3 Prominent Companies in the Market
11.4 World Market Forecasts
11.5 Future Outlook and Concluding Remarks

8. www.visiongain.com Page 32
Blood Glucose Monitoring Devices:
World Market Outlook, 2016-2026
four priority non-communicable diseases (NCD’s) targets by world leaders at the 2011 Political
Declaration on the Prevention and Control of NCDs. The declaration raised the profile of diabetes
and it has since gained recognition on an international scale. This agreement has put pressure on
companies and governments alike to manage the disease effectively, by making disease
management affordable for an increasing population and stepping up efforts of disease prevention.
Table 2.1 High Blood Glucose Age-Standardized Mortality Rates Per 100,000
(Age 20+)
Region Both Sexes Female Male
African Region
111.3 110.9 111.1
Region of the Americas
72.6 63.9 82.8
Eastern Mediterranean Region
139.6 140.2 138.3
European Region 55.7 46.5 64.5
South-East Asia Region
115.3 101.8 129.1
Western Pacific Region
67 65.8 67.8
2.2 Diabetes Monitoring
Patients with diabetes must have a comprehensive understanding of their blood glucose levels,
blood pressure and cholesterol levels in order to successfully manage the condition. Testing blood
glucose, blood pressure and cholesterol levels are crucial, especially in minimising the risk of
longer term complications associated with diabetes, such as heart disease and stroke. Patients
may also receive testing blood glucose, blood pressure and cholesterol levels, as these are crucial,
especially in minimising the risk of longer term complications associated with diabetes, such as
heart disease and stroke.
2.2.1 Glucose Levels
Daily self-monitoring of blood glucose levels is an essential part of diabetes management. Patients
with diabetes must maintain a day to day routine of monitoring their blood glucose levels in order to
keep their blood glucose levels within a healthy range in order to avoid hyper/hypo-glycaemic
events or long term complications. Traditionally such blood glucose tests have been carried out in
a clinical setting by a healthcare professional. Yet, with the advent of modern technology blood
glucose monitoring devices are becoming increasingly smaller and more portable, allowing patients
Source: visiongain 2016, WHO 2016, Colour gradation (from Red to Blue) relates to mortality rates (from High to Low)

9. www.visiongain.com Page 61
Blood Glucose Monitoring Devices:
World Market Outlook, 2016-2026
Figure 5.3 Evolution of Blood Glucose Monitors
5.3.2 Growing Significance of Emerging Markets
The US is currently the largest national market for glucose meters. This is primarily due to the
increased prevalence of diabetes. Current CDC statistics show that as of 2012, 29 million
American residents suffer from diabetes (approximately 9.3% of the total population), of which 7
million remain undiagnosed. It has been estimated that by the end of this decade, diabetes
prevalence in the US will reach up to 15%, owing to the aging population, lack of physical activity
and poor dietary habits. This increased prevalence is in turn prompting manufacturers to introduce
new products and technologies, such monitoring devices that have been integrated with an insulin
pump. Government initiatives to help raise patient awareness and healthcare consciousness about
Source: visiongain 2016

10. www.visiongain.com Page 68
Blood Glucose Monitoring Devices:
World Market Outlook, 2016-2026
6.3 Continuous Glucose Monitoring (CGM) Systems vs. Fingertip Testing
CGMs use a sensor and transmitter attached to the body and connected to a handheld receiver or
insulin pump, monitoring the blood glucose levels every one to five minutes. CGM is useful in
patients who witness vast fluctuations in their glucose levels. The use of CGMs helps such patients
avoid the discomfort of fingertip pricking regularly. The advantages of CGM over traditional
fingertip monitors are mentioned in Table 6.2.
Table 6.2 Advantages of CGMs over Fingerstick Testing Systems, 2016
Prevent the associated pain with pricking
An implantable system can alleviate the problem of lack of patient compliance
Avoid the inconvenience of carrying the glucose monitoring system
Practical consideration can limit the frequency of use of glucometers in critical care,
where blood glucose measurement may be required every 20 minutes.
Since this is a relatively new technology compared to the fingertip monitors, there are only a few
products available in the market. The marketed products are listed in Table 6.3.
Table 6.3 Marketed CGMs, 2016
Category Name Manufacturer
G4 Dexcom
G5 Dexcom
CGM Specific Devices Enlite Medtronic
Freestyle Navigator II Abbott Pharmaceuticals
Freestyle Libre Abbott Pharmaceuticals
Insulin Pumps with CGM
Integration
Vibe Animas Corporation
530 DG With enlite Medtronic Diabetes
T:slim G4 Pump Tandem Diabetes Care
Source: visiongain 2016
Source: visiongain 2016